Faecalibacterium prausnitzii.
The anti-inflammatory powerhouse of your gut One of the biggest butyrate makers in a healthy colon. Butyrate is the fuel colon cells prefer over glucose, so this organism feeds the gut lining from inside.
Reviewed March 2026
- Category
- Probiotic
- Also filed under
- Anti inflammatoryIBD researchButyrate production
What Faecalibacterium prausnitzii is, and what it does.
- Does it work
- Suits people rebuilding gut balance after antibiotics or a rough stretch. It's early technology: the organism dies in air, so packaging and handling decide what arrives.
- How much to take
- Start with one serving a day. The figure that matters is live cells guaranteed at the end of shelf life rather than at packing, because this organism dies on contact with air.
- Time to feel it
- Microbiome shifts show up in stool testing across two to eight weeks. Any change in digestive comfort tends to arrive gradually over that window.
- The first dose
- Day one is quiet. The cells are travelling to the colon, where butyrate output shows up in stool measurement over weeks rather than in how you feel today.
- With regular use
- Weeks to months of daily use is the window where butyrate output and colonisation show up in stool testing. Nothing stays behind once you stop, so any change tracks continued use.
- How well tolerated
- Live cultures are generally well tolerated, with some early gas or looser stools. Anyone with a weakened immune system or a central line should ask their doctor first.
- How it feels
- Most people describe steadier digestion rather than a sensation. Some notice less gurgling and more predictable mornings after a few weeks.
- The overlooked benefit
- It can't eat fibre directly. It lives on acetate other bacteria release, so a fermentable fibre such as inulin or partly hydrolysed guar gum is what actually feeds it.
1 to 5 CFU a day is where Faecalibacterium prausnitzii works.
Source: Sokol et al., Proc Natl Acad Sci, 2008
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Faecalibacterium prausnitzii has emerging evidence. Based on 13502+ studies.
- Butyrate production from acetate and fermentable carbohydrateIn vitro study
- Abundance in a balanced adult gut microbiomeCohort study
- Gut barrier integrityAnimal study
- A healthy inflammatory response in the gut liningAnimal study
- Digestive comfort from live administration in adultsNarrative review
Questions people ask about Faecalibacterium prausnitzii.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Inulin is fermented in the colon to acetate and lactate, the cross-feeding substrates this butyrate producer uses. Supplying the fibre alongside the organism gives it something to grow on rather than relying on background diet.
PHGG ferments slowly along the whole colon and raises butyrate output. That fermentation profile matches where this organism sits and feeds it directly.
Pectin is degraded by primary fermenters into acetate and oligosaccharides. F. prausnitzii takes up that acetate and converts it to butyrate.
Bifidobacteria release acetate and lactate as they ferment oligosaccharides. F. prausnitzii consumes both and turns them into butyrate, the classic cross-feeding chain.
B. lactis acidifies the lumen and supplies acetate. That acetate is the carbon source this butyrate producer draws on.
Akkermansia degrades mucin and releases oligosaccharides and acetate into the mucus layer. Those released sugars are usable by butyrate producers living in the same niche.
Oat beta-glucan is fermented to short-chain fatty acids with a notable butyrate share. It gives the strain fermentable material that survives to the distal colon.
Berberine has broad antibacterial activity in the gut lumen and shifts community composition. Taken in the same dose window it can work against a live commensal you are trying to establish, so spacing them apart is the sensible formulation call.
Carvacrol and thymol disrupt bacterial membranes broadly rather than selectively. Delivered together with a live commensal they reduce the number of viable organisms arriving in the colon.
Charcoal adsorbs small organic molecules indiscriminately in the gut lumen, including fermentation products. Co-dosing is therefore worth avoiding, so the two belong at different times of day.
Resistant starch escapes small-intestinal digestion and arrives in the colon as fermentable substrate. Faecalibacterium prausnitzii is a butyrate producer that grows on the acetate and simple sugars released when primary degraders break that starch down. Supplying substrate is the usual way this organism is supported in the gut; the pairing is a substrate relationship, not a measured clinical outcome.
Galactooligosaccharides are fermented mainly by bifidobacteria, which release acetate and lactate. Faecalibacterium prausnitzii consumes acetate and converts it to butyrate, so cross-feeding is the route by which a bifidogenic fibre can raise butyrate output. The step is well described in fermentation studies of mixed cultures.
Short-chain fructans reach the proximal colon largely intact and are fermented rapidly. The acetate produced feeds acetate-to-butyrate converters including Faecalibacterium prausnitzii. Rapid fermentation also produces gas, which is why tolerance varies between people.
Psyllium is only partially fermented, so it holds water and slows transit while still delivering some substrate to the colonic community. That combination of a gel-forming and a partly fermentable fibre gives butyrate producers a slower, steadier supply than a rapidly fermented oligosaccharide. The claim here is about substrate delivery, not about any measured change in a person.
Butyrate is the end product Faecalibacterium prausnitzii makes from acetate and fermentable carbohydrate, and it is the preferred energy substrate of colonocytes. Supplying butyrate directly delivers the same molecule without requiring the fermentation step. The two approaches converge on the same metabolite, which is why they are usually considered together rather than in isolation.
Lactate from lactobacilli is taken up by lactate-utilising butyrate producers in the colon. Faecalibacterium prausnitzii is among the organisms that benefit from that hand-off in mixed culture. The relationship is described at the level of microbial metabolism, not as a clinical result.
Chicory-derived inulin is a long-chain fructan fermented across the length of the colon. In laying hens, inulin feeding was linked to Faecalibacterium-derived spermidine and to lower liver fat measures, an animal finding rather than human evidence. The substrate relationship itself is standard fermentation biochemistry.
Faecalibacterium can produce spermidine, a polyamine involved in intestinal epithelial renewal. In laying hens given inulin, Faecalibacterium-derived spermidine was reported as the mediating step for lower liver fat measures. This is animal data and a mechanistic marker, not a demonstrated human outcome.
Glutamine is the main fuel of small-intestinal enterocytes, while butyrate from Faecalibacterium prausnitzii fuels colonocytes. The two feed different segments of the same lining rather than competing for one pathway. Nothing here shows a combined effect in people; it is a division of substrate along the gut.
Vitamin D receptor signalling in intestinal epithelium influences tight-junction protein expression and mucosal immune tone, the same barrier machinery butyrate acts on. The overlap is at the level of epithelial signalling and is described mechanistically. No combination trial supports a joint effect.
In a randomised supplementation trial, magnesium was associated with shifts in gut microbiome composition and in bacterial vitamin D metabolism. The report concerns microbial community measures, which are markers rather than clinical outcomes. Whether Faecalibacterium prausnitzii specifically benefits is not settled by that work.
Most catechins pass unabsorbed into the colon, where the resident community cleaves them into smaller phenolics. Those transformations change the local environment butyrate producers grow in, and polyphenol feeding is a recognised way to shift community composition. Direction and size of any effect on Faecalibacterium prausnitzii vary between reports.
Quercetin glycosides are poorly absorbed and reach the colon, where bacterial enzymes deglycosylate and degrade them. The resulting phenolic acids alter the growth environment for anaerobes including butyrate producers. This is a community-level modulation, described in fermentation and animal work rather than clinical trials.
Saccharomyces boulardii is a yeast that transits the gut without colonising and is used to keep the resident community from being crowded out during disruption. Faecalibacterium prausnitzii is one of the organisms that falls when the anaerobic community is disturbed. The pairing rests on ecology rather than on a study of the two together.
Cereal beta-glucan is viscous in the small intestine and fermentable in the colon, producing short-chain fatty acids including butyrate. The fermentation depends on a community with intact butyrate producers. Reported shifts are in microbial and metabolite measures, not clinical endpoints.
Nothing specific on file for Faecalibacterium prausnitzii. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Faecalibacterium prausnitzii actually does.
Faecalibacterium prausnitzii is a strict anaerobe that produces butyrate from acetate and fermentable carbohydrate using the butyryl-CoA:acetate CoA-transferase route.
Butyrate is the preferred energy substrate of colonocytes, which oxidise it in preference to glucose.
The organism is extremely oxygen sensitive and loses viability on air exposure, which is why culture and finished-form handling are done under oxygen exclusion.
Cross-feeding is the normal route by which fibre reaches this organism: primary degraders release acetate and simple sugars, and Faecalibacterium prausnitzii consumes acetate downstream.
Where Faecalibacterium prausnitzii comes from.
It is grown from a strain originally taken from a healthy human gut, in sealed tanks with no air at all, then freeze-dried and packed with the oxygen kept out. The bacterium dies in air, so the whole process is built around that one problem.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
Working strains descend from isolates recovered from human faecal samples, since this species is a normal member of the adult colonic community and has no food-fermentation history.
Growth requires oxygen-free vessels with a reducing agent such as cysteine, plus acetate and riboflavin in the medium. Air exposure at any point kills the culture, which is the reason commercial availability has lagged behind ordinary lactobacilli.
Cells are concentrated by centrifugation or filtration inside a sealed, gas-flushed system rather than in open equipment.
A cryoprotectant matrix is added and the concentrate is standardised on viable cells per gram, measured anaerobically.
Lyophilised material is filled under inert gas into aluminium blister or sealed containers with desiccant and an oxygen scavenger. Some programmes instead deliver the organism as an inactivated preparation, which removes the viability problem and also removes live fermentation.
Getting Faecalibacterium prausnitzii from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The essence, in one line each.
- Across dietary studies, fibre-rich intakes were repeatedly associated with higher levels of butyrate-producing gut bacteria including Faecalibacterium prausnitzii, which the authors describe as a keystone species for colonic energy supply.Systematic review. Snodgrass et al., 2026 (International journal of molecular sciences). PMID 41683715 ↗
- Pooled human trials found polyphenol supplementation was associated with higher relative abundance of Faecalibacterium and increased faecal short-chain fatty acids, with wide variation between studies.Meta-analysis. Alshatari et al., 2026 (Nutrients). PMID 42280405 ↗
- Faecalibacterium prausnitzii supplementation supported intestinal barrier markers and limited microbial community disruption in the model used.Animal study. Wang et al., 2024 (Nutrients). PMID 38674791 ↗
- A nutraceutical blend was reported to shift body weight, inflammatory markers and sleep measures, with Faecalibacterium prausnitzii abundance named as a correlate; abundance is a marker, not an outcome.Randomised trial. Santamarina et al., 2025 (Molecular Nutrition and Food Research). PMID 39981988 ↗
- Inulin feeding raised Faecalibacterium-derived spermidine, which the authors identified as the step mediating lower liver fat measures in the birds studied.Animal study. Yang et al., 2026 (npj Biofilms and Microbiomes). PMID 42259828 ↗
- Faecalibacterium prausnitzii administration reduced lung inflammatory markers in a rodent model, which the authors attributed to gut-to-lung signalling.Animal study. Feng et al., 2026 (Frontiers in Microbiology). PMID 42293544 ↗
- Epithelial syndecan-1 supported mucosal homeostasis in the model used, and the authors linked that effect to increased Faecalibacterium abundance.Animal study. Chen et al., 2026 (Gut Microbes). PMID 42068031 ↗
- The review names Faecalibacterium prausnitzii among the organisms typically depleted in disturbed gut communities and discusses restoration approaches.Narrative review. Lagos et al., 2026 (Pathogens). PMID 42075777 ↗
- Across the studies reviewed, Mediterranean-style eating patterns were associated with higher abundance of butyrate producers including Faecalibacterium; these are associations, not demonstrated causes of cognitive change.Systematic review. Ibeas-Perez et al., 2026 (Frontiers in Molecular Neuroscience). PMID 41884318 ↗
- The review reports lower Faecalibacterium abundance among the microbial patterns described in the older adults studied; this is a correlational abundance measure and not a demonstrated cause of any change in cognition.Systematic review. Katsigianni et al., 2026 (Molecular Neurobiology). PMID 42118364 ↗
- Probiotic use was associated with changes in liver function markers and microbiota composition, with Faecalibacterium named among the affected taxa; markers, not clinical outcomes.Systematic review. Saadh et al., 2025 (Frontiers in Nutrition). PMID 41487669 ↗
- Magnesium supplementation shifted gut microbiome composition and bacterial vitamin D handling in the participants studied; the endpoints are microbial measures.Randomised trial. Sun et al., 2025 (The American Journal of Clinical Nutrition). PMID 40946805 ↗
- A bioconversion-based postbiotic was reported to change muscle strength measures and gut microbiota composition in the participants studied.Randomised trial. Jung et al., 2025 (Nutrients). PMID 41470885 ↗
These are the studies our verdict leans on, chosen from the 6,428 we read for Faecalibacterium prausnitzii. The full linked list is below.
The studies, linked.
6 sources behind our Faecalibacterium prausnitzii verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEffects of Oral Riboflavin Supplementation on the Growth of Faecalibacterium Prausnitzii and the Impact on the Gut Microbiota: A Randomized, Double-blind, Placebo-controlled Human Intervention TrialClinicalTrials.gov ↗PHASE2 · 105 participants · Completed
- Clinical trialThe Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's DiseaseClinicalTrials.gov ↗NA · 70 participants · Completed
- Clinical trialStudy of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic RhinitisClinicalTrials.gov ↗56 participants · Completed
- Clinical trialEffect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s DiseaseClinicalTrials.gov ↗NA · 38 participants · Completed
- Clinical trialA Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's DiseaseClinicalTrials.gov ↗PHASE1 · 8 participants · Terminated
- Clinical trialA Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)ClinicalTrials.gov ↗PHASE1 · 33 participants · Recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.